Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX

Cell Death and Differentiation

Volumn 18, Issue 11, 2011, Pages 1736-1745

  Spinnler, C ^a   Hedstrom E ^a   Li, H ^a   De Lange, J ^b   Nikulenkov, F ^a   Teunisse, A F A S ^b   Verlaan De Vries, M ^b   Grinkevich, V ^a   Jochemsen, A G ^b   Selivanova, G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cancer; HdmX; p53; RITA; Wip1

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; HUMAN DOUBLE MINUTE X PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; RITA PROTEIN; UNCLASSIFIED DRUG; WILD TYPE P53 INDUCED PHOSPHATASE 1;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION;

APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; FURANS; GENE EXPRESSION REGULATION; HUMANS; NUCLEAR PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA;

EID: 80053934582     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2011.45     Document Type: Article

References (40)

1. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604. (Pubitemid 37328926)
2. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA 1999; 96: 14973-14977. (Pubitemid 30019749)
3. Pan Y, Chen J. MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol 2003; 23: 5113-5121. (Pubitemid 36950868)
4. Pereg Y, Shkedy D, de Graaf P, Meulmeester E, Edelson-Averbukh M, Salek M et al. Phosphorylation of Hdmx mediates its Hdm2-and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci USA 2005; 102: 5056-5061.
5. Chen L, Gilkes DM, Pan Y, Lane WS, Chen J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J 2005; 24: 3411-3422. (Pubitemid 41486779)
6. Ramos YF, Stad R, Attema J, Peltenburg LT, van der Eb AJ, Jochemsen AG. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res 2001; 61: 1839-1842. (Pubitemid 32691995)
7. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA et al. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 1999; 59: 6091-6096. (Pubitemid 30035626)
8. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848. (Pubitemid 38174664)
9. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10: 1321-1328. (Pubitemid 40022713)
10. Hedstrom E, Issaeva N, Enge M, Selivanova G. Tumor-specific induction of apoptosis by a p53-reactivating compound. Exp Cell Res 2009; 315: 451-461.
11. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7: 547-559. (Pubitemid 40799248)
12. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282-288. (Pubitemid 34250107)
13. Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R et al. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 2004; 24: 5835-5843. (Pubitemid 38787968)
14. Gilkes DM, Chen L, Chen J. MDMX regulation of p53 response to ribosomal stress. EMBO J 2006; 25: 5614-5625. (Pubitemid 44847201)
15. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci USA 2003; 100: 12009-12014. (Pubitemid 37271506)
16. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 2006; 66: 3169-3176.
17. Wang YV, Wade M, Wong E, Li YC, Rodewald LW, Wahl GM. Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Proc Natl Acad Sci USA 2007; 104: 12365-12370. (Pubitemid 47206143)
18. Pazgier M, Liu M, Zou G, Yuan W, Li C, Li C et al. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci USA 2009; 106: 4665-4670.
19. Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F et al. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 2010; 285: 10786-10796.
20. Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 2008; 27: 123-135.
21. Demidov ON, Timofeev O, Lwin HN, Kek C, Appella E, Bulavin DV. Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine. Cell Stem Cell 2007; 1: 180-190. (Pubitemid 47215589)
22. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci USA 1997; 94: 6048-6053. (Pubitemid 27270633)
23. Lu X, Nannenga B, Donehower LA. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 2005; 19: 1162-1174. (Pubitemid 40696183)
24. Zhang X, Lin L, Guo H, Yang J, Jones SN, Jochemsen A et al. Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response. Cancer Res 2009; 69: 7960-7968.
25. Lu X, Nguyen TA, Donehower LA. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D. Cell Cycle 2005; 4: 1060-1064. (Pubitemid 41365366)
26. Belova GI, Demidov ON, Fornace Jr AJ, Bulavin DV. Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis. Cancer Biol Ther 2005; 4: 1154-1158. (Pubitemid 41598573)
27. Grinkevich V, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009; 15: 441-453.
28. Enge M, Bao W, Hedstrom E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009; 15: 171-183.
29. Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G et al. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res 2009; 69: 6241-6248.
30. Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine AJ, Oren M. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci USA 2000; 97: 11250-11255.
31. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733-1737. (Pubitemid 29428873)
32. de Graaf P, Little NA, Ramos YF, Meulmeester E, Letteboer SJ, Jochemsen AG. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. J Biol Chem 2003; 278: 38315-38324. (Pubitemid 37221723)
33. Yang J, Ahmed A, Poon E, Perusinghe N, de Haven Brandon A, Box G et al. Smallmolecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol 2009; 29: 2243-2253.
34. Lu X, Ma O, Nguyen TA, Jones SN, Oren M, Donehower LA. The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 2007; 12: 342-354. (Pubitemid 47539308)
35. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6: 909-923. (Pubitemid 44862676)
36. Lam S, Lodder K, Teunisse AF, Rabelink MJ, Schutte M, Jochemsen AG. Role of Mdm4 in drug sensitivity of breast cancer cells. Oncogene 2010; 29: 2415-2426.
37. Choi J, Jang H, Kim H, Kim ST, Cho EJ, Youn HD. Histone demethylase LSD1 is required to induce skeletal muscle differentiation by regulating myogenic factors. Biochem Biophys Res Commun 2010; 401: 327-332.
38. Mal A, Sturniolo M, Schiltz RL, Ghosh MK, Harter ML. A role for histone deacetylase HDAC1 in modulating the transcriptional activity of MyoD: inhibition of the myogenic program. EMBO J 2001; 20: 1739-1753. (Pubitemid 32299410)
39. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31: e15.
40. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3 (Article 3).